Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 21, Issue 10, 2009, Pages 1247-1252

  Antoniou, Tony ^a   Raboud, Janet M ^b   Kovacs, Colin ^c   Diong, Christina ^b   Brunetta, Jason ^a   Smith, Graham ^a   Halpenny, Roberta ^a   Beninger, Francis ^c   Loutfy, Mona R ^c  

^a Canadian Immunodeficiency Research Collaborative   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bio Alcamid; Facial lipoatrophy; HIV; Polyalkylimide gel; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; BIO ALCAMID; POLYALKYLIMIDE; POLYMER; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FACE; FACIAL LIPOATROPHY; FEMALE; GEL; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; THERAPY DELAY; TISSUE NECROSIS; TREATMENT OUTCOME;

ACRYLIC RESINS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DERMATOLOGIC AGENTS; FACE; FEMALE; GELS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 70450187064     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120902814379     Document Type: Article

References (17)

1. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15, 2441-2444.
2. James, J., Carruthers, A., & Carruthers, J. (2002). HIVassociated facial lipoatrophy. Dermatologic Surgery, 28, 979-986.
3. Karim, R.B., de Lint, C.A., van Galen, S.R., van Rozelaar, L., Nieuwkerk, P.T., Askarizadeh, E., et al. (2008). Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. Aesthetic Plastic Surgery, 32, 873-878.
4. Karim, R.B., Hage, J.J., van Rozelaar, L., Lange, C.A., & Raaijmakers, J. (2006). Complications of polyalkylimide 4% injections (Bio-Alcamid): A report of 18 cases. Journal of Plastic, Reconstructive & Aesthetic Surgery, 59, 1409-1414.
5. Lewis, V., & Finlay, A.Y. (2004). 10 years experience of the Dermatology Life Quality Index (DLQI). Journal of Investigative Dermatology, Symposium Proceedings of the Society for Investigative Dermatology and European Society for Dermatological Research, 9, 169-180.
6. Loutfy, M.R., Raboud, J.M., Antoniou, T., Kovacs, C., Shen, S., Halpenny, R., et al. (2007). Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS, 21, 1147-1155.
7. Martin, A., & Mallon, P.W. (2005). Therapeutic approaches to combating lipoatrophy: Do they work? Journal of Antimicrobrial Chemotherapy, 55, 612-615.
8. Martin, A., Smith, D.E., Carr, A., Ringland, C., Amin, J., Emery, S., et al. (2004). Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX extension study. AIDS, 18, 1029-1036.
9. Moyle, G.J., Brown, S., Lysakova, L., & Barton, S.E. (2006). Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Medicine, 7, 181-185.
10. Moyle, G.J., Lysakova, L., Brown, S., Sibtain, N., Healy, J., Priest, C., et al. (2004). A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine, 5, 82-87.
11. Oette, M., Juretzko, P., Kroidl, A., Sagir, A., Wettstein, M., Siegrist, J., et al. (2002). Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care and STDS, 16, 413-417.
12. Pacini, S., Ruggiero, M., Morucci, G., Cammarota, N., Protopapa, C., & Gulisano, M. (2002). Bio-Alcamid: A novelty for reconstructive and cosmetic surgery. Italian Journal of Anatomy and Embryology, 107, 209-214.
13. Protopapa, C., Sito, G., Caporale, D., & Cammarota, N. (2003). Bio-AlcamidTM in drug-induced lipodystrophy. Journal of Cosmetic and Laser Therapy, 5, 226-230.
14. Savard, J., Laberge, B., Gauthier, J.G., Ivers, H., & Bergeron, M.G. (1998). Evaluating anxiety and depression in HIV-infected patients. Journal of Personality Assessment, 71, 349-367.
15. Sutinen, J. (2005). Interventions for managing antiretroviral therapy-associated lipoatrophy. Current Opinion in Infectious Diseases, 18, 25-33.
16. Treacy, P.J., & Goldberg, D.J. (2006). Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIVpositive patients undergoing treatment with antiretroviral drugs. Dermatologic Surgery, 32, 804-808.
17. Wu, A.W., Revicki, D.A., Jacobson, D., & Malitz, F.E. (1997). Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Quality of Life Research, 6, 481-493.